

General Inspection Trends in Europe: Current Systems and Future Perspectives

Prof. Dr. Harald G. Schweim

Head of Department for Drug Regulatory Affairs

Institute for Pharmacy, University of Bonn

Former President of the German *Federal Institute for Drugs and Medical Devices* (BfArM)

Former Director of the German Institute of Medical Documentation and Information (DIMDI)

Topics...

1. Current Pharmaceutical Legislation
2. Inspection Systems
3. Types of Inspection in the EU
4. Former Programs with EU-Candidate Countries

Institutions & Cooperations

EMEA European Agency for the
Evaluation of Medicinal
Products
<http://www.emea.eu.int>

EC
European
Commission

Marketing
authorization in
centralized
procedures

EDQM European Directorate for the
Quality of Medicines
<http://www.pheur.org>

Council of
Europe;
inter-govern-
mental

- EP monographs
- Certificate of
EP
- OMCL network

PIC/S Pharmaceutical Inspection
Cooperation Scheme
<http://www.picscheme.org>

Cooperation

Joint standards and
trainings

1. Current Pharmaceutical Legislation

[http:// pharmacos.eudra.org](http://pharmacos.eudra.org)

Relevant European Legislation

Directives	Pharmaceuticals: 2001/83/EC (hum.) & 2001/82/EEC (vet.) GMP-Directives: 91/356/EEC (hum) & 91/412/EEC (vet)	transferred into 15 national member state laws
Regulation	EMA, central authorization & supervision of medicinal products 2309/93/EC	directly binding
Decision	e.g. related to BSE/ TSE	directly binding
Guidelines/ Guidances/ „Soft Law“	GMP – Guide „Rules governing medicinal products“ Compilation of Community Procedures	current standard

Modification & Review Process EC Pharmaceutical Legislation

1. Modification of Directive 2001/82/EC on the Community Code relating to medicinal products for human use,
2. Modification of Directive 2001/83/EC on the Community Code relating to medicinal products for veterinary use
3. Modifications of Council Regulation (EEC) No.2309/93

Modification of Human Directive

Article 47*

- Detailed GMP guidelines for active substances used as starting materials
- Commission to publish guidelines on
 - format and content of authorization
 - inspection reports
 - format and content of GMP certificate

* veterinary directive correspondingly

Modification of Human Directive

Articles 46 & 46a*

- GMP for active substances used as starting materials requested as a necessary provision for manufacturing authorization
- with respect to
 - total & partial manufacture
 - import
- for wholesalers, brokers, traders for e.g. processes as
 - dividing up
 - packaging

* veterinary directive correspondingly

Modification of Human Directive: Supervision & Sanction - Article 111*

Inspection Request	Responsibility
<ul style="list-style-type: none">• Member State (MS)• Commission• EMEA	Competent MS authority
<ul style="list-style-type: none">• Starting material manufacturer• EDQM in the context of CEP (via Commission or EMEA)	

* veterinary directive correspondingly

News in EC GMPs (Annexes)

6	Manufacture of Medicinal Gases	Rev. 07/2002
13	Manufacture of Investigational Medicinal Products	Currently under rev.
14	Manufacture of Products derived from Human Blood or Human Plasma	Rev. 10/2000
15	Qualification and Validation	Rev. 07/2001
16	Certification by a Qualified Person and Batch release	New 07/2001
17	Parametric Release	New 07/2001
18	GMP for APIs (ICH Q7a)	New 07/2001

Inspection Systems

References for Inspectorate Quality Systems

- PIC/S Quality System Requirements for Pharmaceutical Inspectorates (PI 002-1)
- EN 45000 - Series
- ISO 9000 - Series
- Compilation of Community Procedures
- EU Joint Audit Program

Compilation of Community Procedures

- Rapid alerts, recalls
- GMP inspections:
 - » Conduct
 - » Third country inspections
 - » Training of inspectors
- GMP inspection report format
- Format for manufacturing authorization
- Exchange of information within the EU
- Batch certificates in the context of an MRA
- Inspections within the centralized procedure

European Expert Cooperation

Besides formal cooperation in the legislative process:

- Ad hoc Working Groups of GMP/ GCP Inspection Services hosted by EMEA
- Working Groups at EMEA
- Exchange between EU and PIC/S
- European Network coordinated by EDQM

Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) by EDQM

Manufacturer must ensure that ...

- all possible impurities and contamination from this particular route of manufacturer (including source material) can be fully controlled by the monograph.

CEP certifies that ...

- by applying the relevant monographs of European Pharmacopoeia (EP) ...
- it is possible to check whether or not the quality of the substance is suitable for use in medicinal products.

CEP - Procedure

Manufacturer

EDQM

Submission of Dossier

Acknowledgement of receipt

Designation of
Rapporteur & Co-Rapporteur

Report A
Confidential Report

Samples?
Inspections?

Report B
Request for revision of
monograph

Report C
Comments for
inspectors

EDQM

Advisory board

CEP

Types of Inspections in the EU

Pre Marketing Authorization GMP Inspections

- Pre manufacturing authorization inspection
- Dossier related inspections
(up to Member States legislation)

Post Marketing Authorization GMP Inspections

- *Routine inspection*
(every 2 – 3 years with the scope of covering all production areas every 5 years)
- *Product specific inspection*
- *Inspections related to importations*
(in third countries)
- *For cause inspections* (e.g. in case of known product defects)

Inspections in the Context of a Centrally Authorized Product

Ø Product specific inspections

– Pre Approval:

- GMP and dossier related

– Post Approval:

- Routine Inspection (every 2-3 years)
- For Cause Inspection

Ø Lead Inspectorate from EU authority responsible for importing site

(Former) Programs with EU Candidate Countries*

* Maybe this could be a model for „Mediterranean Sea“
surrounding countries ?

PHARE - Program (Regulation 3906/89)

Financial and technical cooperation program of EU with central and eastern European countries

- Implementation of European legislation
- Support of institutions
- Support of investment
- Twinning programs
- Joint programs

Programs in GMP...

Ø *PECA*:

Protocol to the Europe Agreement on Conformity Assessment and Acceptance of Industrial Product

Ø „MRA“ with EU Candidate countries

Ø *PERF*:

Pan European Regulatory Forum

<http://perf.eudra.org>

Ø Joint Training Activities (main focus: GMP)

Ø *CADREAC*:

Collaboration Agreement of Drug Regulatory Authorities in European Associated Countries

Ø Main focus: marketing authorizations

PECCAs – Objectives...

Objectives comparable to those with MRAs:

- Standardized batch certificates
- Exchange of GMP certificates
- No requirement for retesting upon import in EU

... in the view of a future EU membership

PERF - Objectives ...

- ∅ Install regular cooperation
- ∅ Ensure joint training
- ∅ First steps to introduce
 - ∅ EU-legislation
 - ∅ Harmonize systems with the EU

on the long term:

Mutual recognition of authorities

Mutual recognition of marketing authorizations

Steps in PERF

1. Implementation of EC legislation related to medicinal products
2. GMP Training
3. Pharmaco-vigilance/ RAS
4. Marketing authorization
Assessment of dossiers
5. Telematics

**The End or
The Beginning?**